
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/373263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antiâ€ <scp>PD</scp> 1â€induced psoriasis: a study of 21 patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e254-e257.	2.4	144
2	Subcutaneous fat necrosis of the newborn: a systematic evaluation of risk factors, clinical manifestations, complications and outcome of 16 children. British Journal of Dermatology, 2007, 156, 709-715.	1.5	126
3	CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. British Journal of Dermatology, 2003, 149, 170-173.	1.5	108
4	Erythema multiforme and Kawasaki disease associated with COVIDâ€19 infection in children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e539-e541.	2.4	76
5	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatology, 2017, 153, 1147.	4.1	75
6	lvermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. British Journal of Dermatology, 2020, 182, 1003-1006.	1.5	70
7	Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 78-82.	2.4	51
8	Childhood psoriasis. European Journal of Dermatology, 2016, 26, 537-548.	0.6	46
9	Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. British Journal of Dermatology, 2013, 169, 889-895.	1.5	45
10	Outdoor sports and risk of ultraviolet radiation-related skin lesions in children: evaluation of risks and prevention. British Journal of Dermatology, 2011, 165, 360-367.	1.5	43
11	Cyclosporine in childhood psoriasis. Archives of Dermatology, 2001, 137, 1532-3.	1.4	42
12	Psoriasis and obesity in French children: a case-control, multicentre study. British Journal of Dermatology, 2015, 172, 1593-1600.	1.5	41
13	Nail Psoriasis: A Systematic Evaluation in 313 Children with Psoriasis. Pediatric Dermatology, 2017, 34, 58-63.	0.9	41
14	Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. British Journal of Dermatology, 2016, 174, 1118-1121.	1.5	39
15	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 293-300.	2.4	36
16	Medical students and sun prevention: knowledge and behaviours in France. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e247-51.	2.4	33
17	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatology, 2020, 156, 384.	4.1	33
18	High frequency, diversity and severity of skin diseases in a paediatric emergency department. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1468-1475.	2.4	32

#	Article	IF	CITATIONS
19	High frequency of detection of human papillomaviruses associated with epidermodysplasia verruciformis in children with psoriasis. British Journal of Dermatology, 2003, 149, 819-825.	1.5	31
20	Comparison between UV index measurements performed by research-grade and consumer-products instruments. Photochemical and Photobiological Sciences, 2010, 9, 459-463.	2.9	30
21	Factors associated with the choice of the first biologic in psoriasis: realâ€life analysis from the Psobioteq cohort. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2046-2054.	2.4	30
22	Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1984-1992.	2.4	29
23	Neonatal Blue-Light Phototherapy Does Not Increase Nevus Count in 9-Year-Old Children. Pediatrics, 2009, 123, e896-e900.	2.1	27
24	Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Annales De Dermatologie Et De Venereologie, 2016, 143, 264-274.	1.0	27
25	Angioedema in Renal Transplant Recipients on Sirolimus. Dermatology, 2007, 214, 205-209.	2.1	26
26	Validity of satellite measurements used for the monitoring of UV radiation risk on health. Atmospheric Chemistry and Physics, 2011, 11, 13377-13394.	4.9	26
27	Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 151-159.	2.4	26
28	Are sunscreens luxury products?. Journal of the American Academy of Dermatology, 2011, 65, e73-e79.	1.2	24
29	Socioeconomic Inequalities and Severity of Plaque Psoriasis at a First Consultation in Dermatology Centers. Acta Dermato-Venereologica, 2017, 97, 632-638.	1.3	24
30	Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. Archives De Pediatrie, 2019, 26, 86-94.	1.0	20
31	The scalp hair collar and tuft signs: A retrospective multicenter study of 78 patients with a systematic review of the literature. Journal of the American Academy of Dermatology, 2017, 76, 478-487.	1.2	19
32	Impact of the COVID-19 pandemic on children with psoriasis. Annales De Dermatologie Et De Venereologie, 2021, 148, 106-111.	1.0	19
33	Tattoo complications in treated and nonâ€ŧreated psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 888-896.	2.4	17
34	Evaluation of tourists' UV exposure in Paris. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e294-304.	2.4	16
35	Topical Corticosteroid Concerns Among Parents of Children with Psoriasis versus Atopic Dermatitis: A French Multicenter Cross-Sectional Study. American Journal of Clinical Dermatology, 2018, 19, 261-265.	6.7	16
36	Efficacy and safety of <scp>TNF</scp> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2330-2338.	2.4	13

#	Article	IF	CITATIONS
37	French teenagers and artificial tanning. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e428-32.	2.4	12
38	Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists. Dermatologic Therapy, 2018, 31, e12567.	1.7	12
39	Web-based resources for sun protection information – A French-language evaluation. European Journal of Cancer, 2009, 45, 2160-2167.	2.8	11
40	Therapeutic inertia in the management of moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e30-e32.	2.4	11
41	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1578-1583.	2.4	11
42	Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?. Paediatric Drugs, 2019, 21, 169-175.	3.1	10
43	Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France. Annales De Dermatologie Et De Venereologie, 2019, 146, 106-114.	1.0	10
44	Palmoplantar psoriasis, a frequent and severe clinical type of psoriasis in children. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1390-1392.	2.4	9
45	Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases. American Journal of Clinical Dermatology, 2018, 19, 609-615.	6.7	9
46	Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients. British Journal of Dermatology, 2018, 179, 218-219.	1.5	9
47	Proactive treatment in childhood psoriasis. Annales De Dermatologie Et De Venereologie, 2020, 147, 29-35.	1.0	9
48	Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients. Expert Review of Clinical Pharmacology, 2021, 14, 807-819.	3.1	8
49	Compliance with indoor tanning advertising regulations in France. British Journal of Dermatology, 2011, 164, 880-882.	1.5	7
50	Secukinumab efficacy in reducing the severity and the psychosocial impact of moderateâ€ŧoâ€severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSIâ€PSO study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 677-684.	2.4	7
51	Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents. Acta Dermato-Venereologica, 2021, 101, adv00475.	1.3	7
52	Physicians' response to a letter to confirm diagnosis in a genetic study of psoriasis. European Journal of Dermatology, 2002, 12, 66-9.	0.6	6
53	Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr). Paediatric Drugs, 2022, 24, 281-292.	3.1	6
54	Modalités pratiques de photoprotection maximale de l'enfant. Annales De Dermatologie Et De Venereologie, 2007, 134, 88-91.	1.0	5

#	Article	IF	CITATIONS
55	Parents' attitudes related to melanocytic nevus count in children. European Journal of Cancer Prevention, 2010, 19, 472-477.	1.3	5
56	Cushing's Syndrome Induced by Highâ€Potency Topical Corticosteroids in Two Children with Palmoplantar Psoriasis Taking Acitretin. Pediatric Dermatology, 2017, 34, 219-220.	0.9	5
57	Tongue psoriasis: Clinical aspects and analysis of epidemiological associations in 313 children, with a systematic literature review. Annales De Dermatologie Et De Venereologie, 2018, 145, 578-586.	1.0	5
58	Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis. Drugs and Aging, 2020, 37, 657-663.	2.7	5
59	Outâ€ofâ€pocket expenditures in France to manage psoriasis in adult patients: results from an observational, crossâ€sectional, nonâ€comparative, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 912-918.	2.4	5
60	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. Dermatology, 2021, 237, 338-346.	2.1	5
61	Decrease in artificial tanning by French teenagers: 2011â€⊋016. Photodermatology Photoimmunology and Photomedicine, 2018, 34, 257-261.	1.5	4
62	Tattooing and psoriasis: dermatologists' knowledge, attitudes and practices. An international study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e38-e40.	2.4	4
63	Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients. Clinical, Cosmetic and Investigational Dermatology, 2021, Volume 14, 845-854.	1.8	4
64	Dose spacing and reduction strategies in biotherapies for stable, clear or almost clear psoriasis: A survey of practices in France. Annales De Dermatologie Et De Venereologie, 2021, 149, 68-68.	1.0	4
65	Switching biologics in children with psoriasis: Results from the BiPe cohort. Pediatric Dermatology, 2022, 39, 35-41.	0.9	4
66	Safety of ustekinumab in adolescent patients with moderateâ€toâ€severe plaque psoriasis: realâ€world evidence from an ongoing European study (NCT03218488). Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
67	Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study. Dermatology and Therapy, 2022, 12, 1793-1808.	3.0	4
68	Counselling on sun protection, a survey of French paediatricians. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e424-7.	2.4	3
69	Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study. European Journal of Dermatology, 2016, 26, 75-81.	0.6	3
70	Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e269-e272.	2.4	3
71	Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives. Psoriasis: Targets and Therapy, 2020, Volume 10, 45-56.	2.2	3
72	Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study. Dermatology Research and Practice, 2020, 2020, 1-3.	0.8	3

#	Article	IF	CITATIONS
73	Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e301-e303.	2.4	3
74	Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2263-2269.	2.4	3
75	Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological realâ€life practice: The Resoswitch study. Dermatologic Therapy, 2019, 32, e12789.	1.7	2
76	lloprost: a potential alternative for skin graftâ€resistant hypertensive leg ulcer. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e726-e728.	2.4	2
77	Use of mindâ€body practices by patients with psoriasis: results from a study on 2562 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e305-e307.	2.4	2
78	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. British Journal of Dermatology, 2021, 185, 1052-1054.	1.5	2
79	Feelings of guilt in parents of children with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
80	Perceived clinical severity of atopic dermatitis in children: comparison between patients' and parents' evaluation. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
81	Combined acitretin-methotrexate therapy seems safe and efficient in children with psoriasis. Annales De Dermatologie Et De Venereologie, 2022, 149, 189-190.	1.0	2
82	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. Acta Dermato-Venereologica, 2022, 102, adv00733.	1.3	2
83	Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis. British Journal of Dermatology, 2020, 183, 376-378.	1.5	1
84	Crusted scabies in children in France: a series of 20 cases. European Journal of Pediatrics, 2022, 181, 1167-1174.	2.7	1
85	Therapeutic inertia in the management of patients with inadequately controlled atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
86	Perialar intertrigo in children and adolescents: A multicenter prospective study of 41 cases. Pediatric Dermatology, 0, , .	0.9	1
87	Infections cutanées à staphylocoque et streptocoque chez l'enfant. Perfectionnement En Pédiatrie, 2018, 1, 25-31.	0.0	Ο
88	Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in realâ€world clinical setting. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e476-e478.	2.4	0
89	Severe facial dermatitis in a child caused by undisclosed application of skin bleaching agents. Archives De Pediatrie, 2021, 28, 432-433.	1.0	0
90	Topical medications for chronic plaque psoriasis: A 3â€year longitudinal study in France. Dermatologic Therapy, 2021, 34, e14781.	1.7	0

#	Article	IF	CITATIONS
91	Gestion à long terme du psoriasis par les biothérapies. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 5S13-5S21.	0.0	0
92	Alopécie de l'enfant, démarche diagnostique. Perfectionnement En Pédiatrie, 2019, 2, 328-336.	0.0	0
93	Hyperhidrose de l'enfant. Perfectionnement En Pédiatrie, 2020, 3, 266-271.	0.0	0
94	Successful treatment with ixekizumab of lower-limb linear psoriasis in a child. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0